Low-Level HIV RNA Declines Over Time in CSF but not in Plasma
(Presented at 2013 CROI in Atlanta, GA) Summary: This study assayed CSF and plasma samples from ART-treated individuals using an assay capable of quantitating HIV RNA to 2 cp/mL to determine the correlates of low-level HIV RNA with disease, treatment and neurocognitive characteristics.
Detection of HCV RNA in Cerebrospinal Fluid (CSF) Using the Abbott RealTime HCV Assay
(Presented at 2012 HIV DART in San Diego, CA) Summary: This study assessed the Abbott RealTime HCV Assay for its ability to quantitate HCV RNA in CSF.
Case Study: Driving Specialized Testing Through Assay Development
(Presented at the G2 Intelligence MDx Conference, September 13-14, 2012) Summary: Charting the development of a molecular diagnostic assay for an unmet clinical need. Describe the potential benefits of collaborative relationships with pharma and external researchers in bringing up a novel test.
Novel Sample Storage and Transport by ViveST™ for Downstream HCV Viral Load and Genotypic Testing
(Presented at the Next Generation Dx Summit, August 21-23, 2012) Summary: Review of performance data for ViveST, a novel sample storage and transport device, for use with the Abbott RealTime HCV Assay.
Measurement of HCV Viral Load and Viral Genotype from Dried Blood Spots (DBS) and a Dried Ambient Transport Matrix (ViveST) Using the Abbott m2000 System
(Presented at the 2012 International Workshop on HIV and Hepatitis Virus: Drug Resistance and Curative Strategies (IHDRW) in Sitges, Spain) Summary: This study evaluated the use of specimen types other than plasma for HCV diagnostic assays to eliminate logistical limitations and improve clinical management of patients on antiviral therapy in resource-limited settings.
Evaluation of ViveST™ for HIV-1/HCV Testing Using Abbott’s RealTime Assays
(Presented at the 2012 Clinical Virology Symposium (CVS) in Daytona Beach, Florida) Summary: This study compared the performance of ViveST, a novel dried ambient transportation matrix, to frozen plasma for use with commercially available HCV and HIV-1 viral load and genotypic assays.
New HIV-1 SuperLow Assay For Viral Load Monitoring
(Presented at the 2011 Association for Molecular Pathology Annual Meeting in Grapevine, Texas) Summary: Performance review of bioMONTR’s HIV-1 SuperLow Assay for real-time HIV-1 quantitation. The RESEARCH USE ONLY assay has a validated 95% hit rate of 15 c/mL and a reportable range of 2 to 10M c/mL. The HIV-1 SuperLow Assay will be a […]
Utility of HIV-1 EQ SuperLow Viral load Testing in HIV-associated Cognitive Impairment
(Presented at the 2010 III International Clinical Virology Symposium and Advances in Vaccines in Buenos Aires, Argentina) Summary: This study assessed whether low levels of HIV in cerebrospinal fluid (CSF) were associated with inter-individual differences in ART regimens and neuropsychological (NP) performance using bioMONTR’s HIV-1 SuperLow assay.
HIV-1 SuperLow Viral Load as a Monitoring Tool for Antiretroviral Drug Penetration
(Presented at the 2009 Mdx Conference) Summary: Review of bioMONTR’s HIV-1 SuperLow Assay as a monitoring tool for antiretroviral drug penetration.